These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 31161538)

  • 21. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
    Siefker-Radtke AO; Necchi A; Park SH; García-Donas J; Huddart RA; Burgess EF; Fleming MT; Rezazadeh Kalebasty A; Mellado B; Varlamov S; Joshi M; Duran I; Tagawa ST; Zakharia Y; Akapame S; Santiago-Walker AE; Monga M; O'Hagan A; Loriot Y;
    Lancet Oncol; 2022 Feb; 23(2):248-258. PubMed ID: 35030333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
    Loriot Y; Necchi A; Park SH; Garcia-Donas J; Huddart R; Burgess E; Fleming M; Rezazadeh A; Mellado B; Varlamov S; Joshi M; Duran I; Tagawa ST; Zakharia Y; Zhong B; Stuyckens K; Santiago-Walker A; De Porre P; O'Hagan A; Avadhani A; Siefker-Radtke AO;
    N Engl J Med; 2019 Jul; 381(4):338-348. PubMed ID: 31340094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infigratinib: First Approval.
    Kang C
    Drugs; 2021 Jul; 81(11):1355-1360. PubMed ID: 34279850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer.
    Garje R; An J; Obeidat M; Kumar K; Yasin HA; Zakharia Y
    Oncologist; 2020 Nov; 25(11):e1711-e1719. PubMed ID: 32790011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor.
    Wu L; Zhang C; He C; Qian D; Lu L; Sun Y; Xu M; Zhuo J; Liu PCC; Klabe R; Wynn R; Covington M; Gallagher K; Leffet L; Bowman K; Diamond S; Koblish H; Zhang Y; Soloviev M; Hollis G; Burn TC; Scherle P; Yeleswaram S; Huber R; Yao W
    J Med Chem; 2021 Aug; 64(15):10666-10679. PubMed ID: 34269576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy.
    Tully KH; Jütte H; Wirtz RM; Jarczyk J; Santiago-Walker A; Zengerling F; Breyer J; Sikic D; Kriegmair MC; von Hardenberg J; Wullich B; Taubert H; Weyerer V; Stoehr R; Bolenz C; Burger M; Porubsky S; Hartmann A; Roghmann F; Erben P; Eckstein M
    Urology; 2021 Nov; 157():93-101. PubMed ID: 34153367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors.
    Qin Q; Patel V; Galsky MD
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):503-512. PubMed ID: 32436413
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
    Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors.
    Nishina T; Takahashi S; Iwasawa R; Noguchi H; Aoki M; Doi T
    Invest New Drugs; 2018 Jun; 36(3):424-434. PubMed ID: 28965185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plain language summary of erdafitinib in locally advanced or metastatic urothelial carcinoma: a phase 2 study with long-term follow-up.
    Loriot Y; O'Hagan A; Siefker-Radtke AO
    Future Oncol; 2024 Feb; 20(5):231-243. PubMed ID: 37916514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Erdafitinib for locally advanced or metastatic urothelial carcinoma.
    Siefker-Radtke AO; Loriot Y
    Am J Health Syst Pharm; 2022 May; 79(11):824-825. PubMed ID: 35147178
    [No Abstract]   [Full Text] [Related]  

  • 32. Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia.
    Hudkins RL; Allen E; Balcer A; Hoffman ID; Iyer S; Neal M; Nelson KJ; Rideout M; Ye Q; Starrett JH; Patel P; Harris T; Swanson RV; Bensen DC
    J Med Chem; 2024 Sep; 67(18):16737-16756. PubMed ID: 39258897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Durvalumab: First Global Approval.
    Syed YY
    Drugs; 2017 Aug; 77(12):1369-1376. PubMed ID: 28643244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations.
    Lima NC; Atkinson E; Bunney TD; Katan M; Huang PH
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32370101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain
    Franza A; Pirovano M; Giannatempo P; Cosmai L
    Future Oncol; 2022 Jun; 18(19):2455-2464. PubMed ID: 35387485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.
    Li X; Guise CP; Taghipouran R; Yosaatmadja Y; Ashoorzadeh A; Paik WK; Squire CJ; Jiang S; Luo J; Xu Y; Tu ZC; Lu X; Ren X; Patterson AV; Smaill JB; Ding K
    Eur J Med Chem; 2017 Jul; 135():531-543. PubMed ID: 28521156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of the FGF/FGFR System Induces Apoptosis in Lung Cancer Cells via c-Myc Downregulation and Oxidative Stress.
    Giacomini A; Taranto S; Rezzola S; Matarazzo S; Grillo E; Bugatti M; Scotuzzi A; Guerra J; Di Trani M; Presta M; Ronca R
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33317057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
    Guercio BJ; Sarfaty M; Teo MY; Ratna N; Duzgol C; Funt SA; Lee CH; Aggen DH; Regazzi AM; Chen Z; Lattanzi M; Al-Ahmadie HA; Brannon AR; Shah R; Chu C; Lenis AT; Pietzak E; Bochner BH; Berger MF; Solit DB; Rosenberg JE; Bajorin DF; Iyer G
    Clin Cancer Res; 2023 Nov; 29(22):4586-4595. PubMed ID: 37682528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Case Report: Erdafitinib-induced Central Serous Chorioretinopathy.
    Claiborne RT; Tsan GL
    Optom Vis Sci; 2022 Jan; 99(1):88-92. PubMed ID: 34882600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic Effect of FGFR Mutations or Gene Fusions in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Results from a Large, Single-institution Cohort.
    Necchi A; Lo Vullo S; Raggi D; Gloghini A; Giannatempo P; Colecchia M; Mariani L
    Eur Urol Focus; 2019 Sep; 5(5):853-856. PubMed ID: 29525380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.